EED Inhibitor Solid Dispersion for Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EED inhibitors, such as compound A, have poor water solubility and fluidity, leading to low dissolution and bioavailability, which limits their therapeutic efficacy in treating EED-mediated diseases like cancer.
Innovation Solution
A stable solid dispersion is developed comprising an EED inhibitor, particularly compound A, combined with a polymeric carrier like HPMCAS LG or Eudragit, to enhance solubility and bioavailability through amorphous crystal conversion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EED inhibitor compound A is used directly, then it exhibits anti-tumor activity, but it has poor water solubility and low bioavailability
Solution Approach 1:
The patent changes the physical and chemical parameters of the EED inhibitor by converting it from a crystalline state to an amorphous state through solid dispersion technology. This parameter change dramatically improves water solubility and bioavailability while maintaining the anti-tumor activity of the compound
Solution Approach 2:
The patent creates a composite material system by combining the EED inhibitor with polymeric carriers (such as HPMCAS LG or Eudragit) to form solid dispersions. This composite approach enhances the solubility and bioavailability of the poorly water-soluble drug compound
2Ease of operation
If EED inhibitor compound A is used directly, then it exhibits anti-tumor activity, but it has poor fluidity
Solution Approach 1:
The patent changes the physical state parameter of the EED inhibitor from crystalline to amorphous through solid dispersion, which significantly improves fluidity and processability while preserving the molecular structure and anti-tumor activity of the active compound
3Reliability
If solid dispersion is used to improve solubility, then bioavailability increases, but formulation complexity increases
Solution Approach 1:
The patent uses polymeric carriers as intermediary substances to facilitate the transformation of the EED inhibitor into a highly soluble amorphous state. These carriers act as mediators that stabilize the amorphous form and enhance solubility without requiring complex formulation processes
Solution Approach 2:
The patent applies parameter changes by controlling the physical state of the drug in the solid dispersion system, transforming it from crystalline to amorphous. This single parameter change achieves significant bioavailability improvement with relatively simple formulation approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersion improves the dissolution and bioavailability of EED inhibitors, providing effective treatment options for EED-mediated diseases with enhanced therapeutic efficacy.
Implementation Method 1
A stable solid dispersion is developed comprising an EED inhibitor, particularly compound A, combined with a polymeric carrier like HPMCAS LG or Eudragit, to enhance solubility and bioavailability through amorphous crystal conversion.
Data Source
Figure 1A~1B
Figure 1C
Figure 2
AI summary
The present disclosure relates to the field of pharmaceutical formulations, and particularly relates to a solid dispersion having good dissolution and good bioavailability and comprising an embryonic ectoderm development (EED) inhibitor and a preparation method therefor, a solid dispersion composition comprising the solid dispersion and an excipient, and an oral formulation comprising the solid dispersion or the solid dispersion composition, as well as a preparation method therefor, and use of the solid dispersion, the solid dispersion composition, or the oral formulation in treating and/or preventing an EED-mediated disease.